Table 2.

Factors influencing intrahepatic recurrence-free survival and overall survival after stereotactic body radiotherapy

	Intrahepatic recurrence-free survival rates				Overall survival rates
	Univariate analysis		Multivariate analysis		Univariate analysis		Multivariate analysis
Variables	HR (95% CI)	p value	HR (95% CI)	p value	HR (95% CI)	p value	HR (95% CI)	p value
Gender (male)	0.879 (0.490–1.577)	0.666			0.531 (0.184–1.529)	0.241
Age	1.021 (0.998–1.045)	0.076	1.025 (1.001–1.049)	0.039	1.024 (0.977–1.074)	0.319
ECOG performance status (0)a	0.751 (0.403–1.397)	0.365			0.457 (0.147–1.420)	0.176	–	–
Child-Pugh class (A)	1.102 (0.699–1.737)	0.677			0.458 (0.259–0.808)	0.007	0.463 (0.262–0.817)	0.008
Viral aetiology (HBV)b	0.928 (0.459–1.877)	0.836			0.440 (0.140–1.382)	0.160	–	–
Tumor size	1.006 (0.726–1.393)	0.971			0.863 (0.385–1.938)	0.721
Alpha-fetoprotein	1.000 (1.000–1.001)	0.628			0.998 (0.990–1.006)	0.664
PIVKA-II	1.000 (1.000–1.000)	0.448			0.999 (0.995–1.003)	0.712
No. of prior treatment sessions	1.076 (1.024–1.131)	0.004	1.087 (1.031–1.146)	0.002	0.891 (0.735–1.080)	0.238

HR hazard ratio, CI confidence interval, ECOG Eastern Cooperative Oncology Group, HBV hepatitis B virus, PIVKA-II prothrombin induced by vitamin K absence-II

^aCategorical variables are divided as ECOG performance status 0 vs. 1–2

^bCategorical variables are divided as HBV (+) vs. HBV (−)